Imagine a doctor looking at a patient and saying, “There is a medicine that could save your life, but its cost is beyond your reach.”
Is that the success of pharmaceutical innovation, or a failure of healthcare accessibility?
This question lies at the heart of an ongoing debate surrounding pharmaceutical patents, drug pricing, and access to affordable medicines. While patents play a vital role in encouraging medical innovation and research, they can also create challenges for patients who struggle to afford life-saving treatments.
Pharmaceutical patents were introduced to encourage innovation. Developing a new medicine is neither quick nor easy. It often requires more than a decade of research, extensive testing, and enormous financial investment. Scientists dedicate years of effort, overcoming setbacks and failures, to discover treatments that can improve or save lives.
For this reason, patents play an important role. They protect inventions, reward creativity, and motivate pharmaceutical companies to continue investing in medical research and drug development.
However, there is another side to the story. Patents provide exclusive rights to manufacture and sell a drug for a specific period. During this time, competition is limited, and medicine prices can remain extremely high. While this exclusivity helps companies recover their investments and fund future research, it can also create barriers to healthcare access.
Now consider a country like India, where many people still struggle to meet basic healthcare expenses. For countless families, costly medicines are not merely expensive; they are completely inaccessible.
A powerful example comes from the fight against HIV/AIDS. In the early 2000s, the annual cost of HIV treatment exceeded ₹10,00,000 per patient. Such prices placed life-saving therapy beyond the reach of millions. When generic medicines, particularly those produced by Indian pharmaceutical manufacturers, entered the market, the cost dropped dramatically to less than ₹10,000 per year.
This was not just a reduction in price. It was a transformation that enabled millions of people to receive treatment and continue living healthier lives.
Another well-known example is Nexavar, a medicine used in cancer treatment. Initially, its monthly cost in India was approximately ₹2.8 lakh. Following the granting of a compulsory licence that allowed the production of a generic version, the price fell to around ₹8,800.
Consider that difference: from lakhs of rupees to just a few thousand.
From something impossible for most families to something far more attainable.
This brings us to an important question.
Do patents encourage innovation?
Without doubt, they do.
Can they also limit access to essential medicines?
In many situations, yes.
And that is the challenge before us.
The goal should not be to choose between innovation and accessibility. Instead, we must find a balance that supports both.
Governments and policymakers should ensure that pharmaceutical companies receive fair rewards for their discoveries while ensuring that life-saving medicines remain accessible to those who need them. Measures such as compulsory licensing, support for generic medicines, fair-pricing policies, and efforts to improve healthcare access can help achieve this balance.
The debate surrounding pharmaceutical patents, drug affordability, and access to medicines does not have a simple answer. Innovation must be encouraged, as new medicines require years of research, scientific expertise, and significant investment. At the same time, access to affordable healthcare and essential medicines must remain a priority.
After all, healthcare should never be viewed as a privilege reserved for a few.
It is a fundamental human right.
When a medicine exists but remains out of reach because of its price, society must ask whether we are truly serving humanity.
Let us work toward a future where medical innovation continues to flourish, but where no one is denied treatment because they cannot afford it.
Let us value invention but also value human life.
Let us pursue progress with responsibility, innovation with compassion, and healthcare with equity.
Gargee Bantee
Final Year B.Pharm
AISSMS College of Pharmacy